Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma - Concepedia

Concepedia

Publication | Closed Access

Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma

217

Citations

34

References

2013

Year

Wim H.J. Kruit, Stefan Suciu, Brigitte Dréno, Laurent Mortier, Caroline Robert, Vanna Chiarion‐Sileni, Michele Maio, Alessandro Testori, Thierry Dorval, Jean‐Jacques Grob,

Journal of Clinical Oncology

Abstract

In the MAGE-A3+AS15 arm, clinical activity was higher and the immune response more robust. Therefore, the AS15 immunostimulant was selected for combination with the MAGE-A3 protein in phase III trials.

References

	Year	Citations

Page 1